真实世界背景下免疫抑制与支持治疗对IgA肾病肾脏结局的影响
基于中国全国登记数据(2019年1月至2022年5月)的倾向评分匹配队列,纳入3946例IgA肾病患者(免疫抑制组1973例,支持治疗组1973例)。与支持治疗相比,免疫抑制治疗与主要复合终点事件风险降低40%相关(校正HR 0.60,95%CI 0.48-0.75),但严重不良事件更常见。
要点
- 免疫抑制治疗与主要肾脏复合终点风险降低40%相关(校正HR 0.60,95%CI 0.48-0.75)。
- 糖皮质激素单药与吗替麦考酚酯单药观察到相似效应量。
- 免疫抑制组严重不良事件比支持治疗组更频繁。
核心结论
- 与支持治疗相比,免疫抑制治疗与IgA肾病患者临床重要肾脏结局风险降低40%相关。
研究设计与样本
- 基于中国全国登记数据(2019年1月至2022年5月)的倾向评分匹配队列研究,纳入3946例IgA肾病患者,其中免疫抑制新用户1973例、支持治疗匹配接受者1973例。
主要发现
- 共观察到396例主要复合终点事件,免疫抑制组156例(8%),支持治疗组240例(12%)。
- 与支持治疗相比,免疫抑制治疗与主要终点事件风险降低40%相关(校正HR 0.60,95%CI 0.48-0.75)。
- 糖皮质激素单药与吗替麦考酚酯单药观察到可比效应量。
- 预设亚组分析中,免疫抑制治疗效果在年龄、性别、基线蛋白尿水平和基线eGFR值各亚组间一致。
- 免疫抑制组严重不良事件比支持治疗组更频繁。
关键数值与推荐
- 主要终点为基线eGFR下降40%、肾衰竭和全因死亡的复合终点。
- 免疫抑制组主要复合终点事件156例(8%),支持治疗组240例(12%)。
- 校正HR 0.60(95%CI 0.48-0.75)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of immunosuppression in the management of immunoglobulin A (IgA) nephropathy remains highly controversial. The study was conducted to assess the effect of immunosuppression, compared with supportive care, in the real-world setting of IgA nephropathy. METHODS: A cohort of 3946 patients with IgA nephropathy, including 1973 new users of immunosuppressive agents and 1973 propensity score-matched recipients of supportive care, in a nationwide register data from January 2019 to May 2022 in China was analyzed. The primary outcome was a composite of 40% eGFR decrease of the baseline, kidney failure, and all-cause mortality. A Cox proportional hazard model was used to estimate the effects of immunosuppression on the composite outcomes and its components in the propensity score-matched cohort. RESULTS: Among 3946 individuals (mean [SD] age 36 [10] years, mean [SD] eGFR 85 [28] ml/min per 1.73 m 2 , and mean [SD] proteinuria 1.4 [1.7] g/24 hours), 396 primary composite outcome events were observed, of which 156 (8%) were in the immunosuppression group and 240 (12%) in the supportive care group. Compared with supportive care, immunosuppression treatment was associated with 40% lower risk of the primary outcome events (adjusted hazard ratio, 0.60; 95% confidence interval, 0.48 to 0.75). Comparable effect size was observed for glucocorticoid monotherapy and mycophenolate mofetil alone. In the prespecified subgroup analysis, the treatment effects of immunosuppression were consistent across ages, sexes, levels of proteinuria, and values of eGFR at baseline. Serious adverse events were more frequent in the immunosuppression group compared with the supportive care group. CONCLUSIONS: Immunosuppressive therapy, compared with supportive care, was associated with a 40% lower risk of clinically important kidney outcomes in patients with IgA nephropathy.
引用
- Zhao H, Li Y, Sun J, et al. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting. Clin J Am Soc Nephrol. 2023. PMID: 37314777. doi:10.2215/CJN.0000000000000215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。